Evaluation of follow-up of therapy with fenbendazole incorporated into stabilized liposomes and immunomodulator glucan in mice infected with Toxocara canis larvae.
Anthelmintic activity of benzimidazole carbamate anthelmintics is low against dormant Toxocara canis larvae during late infections in paratenic hosts. The present study was conducted to examine the efficacy of pure fenbendazole, or drug incorporated into sterically stabilized liposomes (SL-FBZ) administered to T. canis-infected mice alone and after its co-administration with the immunomodulator (1-->3)-beta-D-glucan against larvae localized in muscles and brains. Therapy with either drug forms (in total 250 mg/kg in 10 doses) commenced on day 28 post-infection (p.i.) and the efficacy of treatment, examined on day 30 after the last dose of drug, was the highest in groups of mice treated with SL-FBZ in combination with glucan (89.5+/-5.8% in the muscles, 66.1+/-8.1% in brains). During 56 days of follow-up after termination of therapy, serum levels of anti-TES IgG antibodies, circulating IgG-TES immune complexes (CIC) as well as IgG antibodies to the most immunogenic part of recombinant myosin antigen of T. canis larvae were investigated. In contrast to anti-TES IgG antibodies, levels of CIC and anti-myosin antibodies were in the linear correlation with the efficacy of treatments beginning from day 38 post-therapy. We also showed that the serum levels of CIC as well as anti-myosin IgG antibodies seem to be the suitable serological markers for the monitoring of progress in larval destruction and TES resorption from the tissues.
Hrckova
G
G
Parasitological Institute of the Slovak Academy of Sciences, Hlinkova 3, 04001 Kosice, Slovak Republic. hrcka@saske.sk
Velebný
S
S
Obwaller
A
A
Auer
H
H
Kogan
G
G
D000818:Animals; D000909:Antibodies, Helminth / Q000097:blood; D015153:Blotting, Western; D001921:Brain / Q000187:drug effects / Q000469:parasitology; D004359:Drug Therapy, Combination; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D005273:Fenbendazole / Q000737:chemistry / Q000627:therapeutic use*; D005936:Glucans / Q000737:chemistry / Q000627:therapeutic use*; D015801:Helminth Proteins / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood; D007155:Immunologic Factors / Q000737:chemistry / Q000627:therapeutic use; D007814:Larva / Q000187:drug effects / Q000276:immunology; D008081:Liposomes / Q000737:chemistry; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009132:Muscles / Q000187:drug effects / Q000469:parasitology; D009218:Myosins / Q000276:immunology; D017166:Toxocara canis / Q000276:immunology*; D014120:Toxocariasis / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology; D016896:Treatment Outcome
D000909:Antibodies, Helminth; D005936:Glucans; D015801:Helminth Proteins; D007074:Immunoglobulin G; D007155:Immunologic Factors; D008081:Liposomes; D005273:Fenbendazole; D009218:Myosins